Startups channel feed – Endpoints News

Startups channel feed

Ex-Pfizer CEO's startup Centrexion gets $67M for PhIII painkiller

8 years ago

Google backs a $60M transition round for FLX’s switch to a CCR4 strategy

8 years ago

In gene therapy's second big win this week, Orchard nabs $110M Series B

8 years ago

Flagship adds $618M in new funds to fuel startup mission

8 years ago

Jnana launches with $50M to spotlight an unexplored protein territory

8 years ago

Its underlying biology 'too complicated' for further investment, Atlas-seeded Raze signs off

8 years ago

Ex-Dezima CEO co-founds NASH startup, flying into Phase IIB with €25 million

8 years ago

Rich Heyman's Metacrine grabs a $22M round in search of a superior NASH drug

8 years ago

Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round

8 years ago

Looking to cure Type 1 diabetes, investors front $114M to launch a pioneering human study at Semma

8 years ago

Frazier backs MavuPharma’s $20M round, brings in heavyweight execs to lead

8 years ago

Doug Williams ups the ante at Codiak Bio to $168.5M in a drive to first human study

8 years ago

Regeneron and Decibel aren’t just collaborating: They want to create a whole new partnering model

8 years ago

Flagship, Arch cut their losses, quietly shutter Ensemble Therapeutics as pipeline plans fizzle out

8 years ago

What's a successful failure? Atlas' Booth sounds taps for Merck-backed Quartet Medicine

8 years ago

$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come

8 years ago

Torque takes tumor tech out of stealth with $25M backing, new CEO

8 years ago

Google backs I/O startup Arcus in $107M deal

8 years ago

Upstart Oyster Point has big plans for disrupting the ophthalmology space, but you'll have to wait for the details

8 years ago

Bill Gates and rich allies help fund an alt-biotech startup path for the gene expression experts at Exicure

8 years ago

Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs

8 years ago

California upstart Xyphos wants to tackle CAR-T's big problems

8 years ago

Atlas-incubated Kymera leaps out of stealth mode, joins the hunt for game-changing protein degradation drugs

8 years ago

Google’s GV and allies double down on Forty Seven with their second $75M round

8 years ago

First page Previous page 66 67 686970 71 72 Next page Last page